SUPERNUS PHARMACEUTICALS, INC.
For the period ended Mar 31, 2026. Filed May 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 5, 2026
SUPN$28.75+4.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Loss
(in thousands, except share and per share data)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2026 | 2025 | |
| (unaudited) | ||
| Revenues | ||
| Net product sales | $150,753 | $141,988 |
| Collaboration revenue (ZURZUVAE) | 27,643 | — |
| Royalty, licensing, and other revenues | 29,309 | 7,836 |
| Total revenues | 207,705 | 149,824 |
| Costs and expenses | ||
| Cost of revenues(a) | 23,391 | 15,763 |
| Research and development | 39,438 | 26,927 |
| Selling, general and administrative | 125,173 | 89,944 |
| Amortization of intangible assets | 25,644 | 19,786 |
| Contingent consideration loss | 2,391 | 7,660 |
| Total costs and expenses | 216,037 | 160,080 |
| Operating loss | (8,332) | (10,256) |
| Other income (expense) | ||
| Interest and other income, net | 2,382 | 4,425 |
| Total other income (expense), net | 2,382 | 4,425 |
| Loss before income taxes | (5,950) | (5,831) |
| Income tax expense (benefit) | (3,657) | 5,996 |
| Net loss | $(2,293) | $(11,827) |
| Loss per share | ||
| Basic | $(0.04) | $(0.21) |
| Diluted | $(0.04) | $(0.21) |
| Weighted average shares outstanding | ||
| Basic | 57,647,548 | 55,864,692 |
| Diluted | 57,647,548 | 55,864,692 |
(a) Excludes amortization of intangible assets
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.